Latest research into retatrutide peptide demonstrate notable outlook for managing weight and type 2 disease. The peptide, a dual activator of GLP-1 receptor and GIP receptor, looks to present enhanced weight loss and glycemic control versus existing medications. Ongoing patient studies are required to thoroughly assess its well-being record and sus